预约演示
更新于：2025-05-16
Travoprost/Timolol Maleate
曲伏噻吗
更新于：2025-05-16
概要
基本信息
药物类型 小分子化药 |
别名 DuoTrav APS、DuoTrav BAK、DuoTrav PQ + [11] |
作用方式 激动剂、拮抗剂 |
作用机制 PTGFR激动剂(前列腺素FP受体激动剂)、β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂) |
治疗领域 |
非在研适应症- |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C39H59F3N4O9S |
InChIKeyKJNUGXGYVXURJB-DDANCUEQSA-N |
CAS号874755-80-3 |
关联
41
项与 曲伏噻吗 相关的临床试验NCT02730871
Safety and Efficacy With Twice Daily Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) as an Adjunctive Therapy to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®)
NCT03966560
Choroidal Thickness and Its Correlations With Ocular Parameters in Cases With Primary Open-angle Glaucoma
NCT02003391
Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTrav® in Patients Previously Uncontrolled on a Beta-blocker
100 项与 曲伏噻吗 相关的临床结果
登录后查看更多信息
100 项与 曲伏噻吗 相关的转化医学
登录后查看更多信息
100 项与 曲伏噻吗 相关的专利（医药）
登录后查看更多信息
89
项与 曲伏噻吗 相关的文献（医药）2024-08-01VACCINE
Single immunization of non-adjuvanted recombinant TTFC-mi3 nanoparticle vaccine elicited a rapid and potent protective immunity against tetanus
Article
作者: Zhang, Yi ; Luo, Ping ; Wu, Meilin ; Cheng, Xin ; Li, Yuhang ; Wang, Yi ; Gu, Jiang ; He, Qinggang ; Li, Xiaoyan ; Chen, Yuan ; Wan, Jiqing
The conventional inactivated tetanus toxin plays an instrumental role in preventing tetanus. Nevertheless, the challenges associated with its production process, the potential for adverse reactions, and reduced effectiveness in vulnerable populations such as neonates and the elderly rise the need for a novel tetanus toxin vaccine. Recombinant subunit vaccine offer a viable solution, and the tetanus toxin fragment C (TTFC) is emerging as a promising candidate. In this study, through spontaneous isopeptide bond formation we conjugated the recombinant TTFC to self-assembled mi3 nanoparticle, which derived from an optimized KDPG aldolase, and generated the TTFC-mi3 protein nanoparticle vaccine. We found that TTFC-mi3 is stable, uniform spherical nanoparticles. Comparing with the free TTFC alone, TTFC-mi3 enhances the uptake and subsequent activation of dendric cells (DCs). In addition, a single dose of adjuvant-free TTFC-mi3 elicited a more rapid and potent protective immunity in mice. Moreover, TTFC-mi3 is of favorable safety in vitro and in vivo. Our findings indicate that TTFC-mi3 is a rapid-response, non-aluminum-adjuvanted vaccine against tetanus.
2022-09-05Journal of epidemiology3区 · 医学
Association of the Time to First Cigarette and the Prevalence of Chronic Respiratory Diseases in Chinese Elderly Population
3区 · 医学
ArticleOA
作者: Lou, Yiling ; Jiang, Heng ; Guo, Yingying ; Tian, Qingfeng ; Cao, Shiyi ; Gan, Yong ; Wang, Chao ; Zhu, Yi ; Lu, Zuxun
BACKGROUND:
Increasing number of studies have suggested the time to first cigarette after waking (TTFC) have significant positive effect on respiratory diseases. However, few of them focused on the Chinese population. This study aims to estimate the impact of TTFC on the prevalence of chronic respiratory diseases (CRD) in Chinese elderly and explore the association in different sub-populations.
METHODS:
Cross-sectional data of demographic characteristics, living environment, smoking-related variables, and CRD were drawn from the Chinese Longitudinal Healthy Longevity Survey in 2018. Multivariate stepwise logistic regression analyses were conducted to examine the association of the TTFC with the prevalence of CRD.
RESULTS:
This study includes 13,208 subjects aged 52 years and older, with a mean age of 85.3 years. Of them, 3,779 participants were ex- or current smokers (44.9% had the TTFC ≤30 minutes, 55.1% >30 minutes) and 1,492 had suffered from CRD. Compared with non-smokers, participants with TTFC ≤30 minutes seemed to have higher prevalence of CRD (OR 1.97; 95% CI, 1.65-2.35) than those with TTFC >30 minutes (OR 1.70; 95% CI, 1.44-2.00), although the difference was statistically insignificant (Pinteraction = 0.12). Compared with TTFC >30 minutes, TTFC ≤30 minutes could drive a higher prevalence of CRD among female participants, those aged 90 years and older, urban residents, and ex-smokers (Pinteraction < 0.05).
CONCLUSION:
Shorter TTFC relates to higher prevalences of CRD in Chinese older females, those aged 90 years and older, urban residents, and ex-smokers. Delaying TTFC might partially reduce its detrimental impact on respiratory disease in these specific subpopulations.
2020-12-01Microbial cell factories2区 · 工程技术
A probiotic treatment increases the immune response induced by the nasal delivery of spore-adsorbed TTFC
2区 · 工程技术
ArticleOA
作者: Baccigalupi, Loredana ; Isticato, Rachele ; Mazzoli, Arianna ; Santos, Francisco Denis S ; Iossa, Susanna ; Ricca, Ezio ; Maia, Ana Raquel ; Saggese, Anella ; Leite, Fabio
Abstract:
Background:
Spore-forming bacteria of the Bacillus genus are widely used probiotics known to exert their beneficial effects also through the stimulation of the host immune response. The oral delivery of B. toyonensis spores has been shown to improve the immune response to a parenterally administered viral antigen in mice, suggesting that probiotics may increase the efficiency of systemic vaccines. We used the C fragment of the tetanus toxin (TTFC) as a model antigen to evaluate whether a treatment with B. toyonensis spores affected the immune response to a mucosal antigen.
Results:
Purified TTFC was given to mice by the nasal route either as a free protein or adsorbed to B. subtilis spores, a mucosal vaccine delivery system proved effective with several antigens, including TTFC. Spore adsorption was extremely efficient and TTFC was shown to be exposed on the spore surface. Spore-adsorbed TTFC was more efficient than the free antigen in inducing an immune response and the probiotic treatment improved the response, increasing the production of TTFC-specific secretory immunoglobin A (sIgA) and causing a faster production of serum IgG. The analysis of the induced cytokines indicated that also the cellular immune response was increased by the probiotic treatment. A 16S RNA-based analysis of the gut microbial composition did not show dramatic differences due to the probiotic treatment. However, the abundance of members of the Ruminiclostridium 6 genus was found to correlate with the increased immune response of animals immunized with the spore-adsorbed antigen and treated with the probiotic.
Conclusion:
Our results indicate that B. toyonensis spores significantly contribute to the humoral and cellular responses elicited by a mucosal immunization with spore-adsorbed TTFC, pointing to the probiotic treatment as an alternative to the use of adjuvants for mucosal vaccinations.
100 项与 曲伏噻吗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 青光眼 | 日本 | 2010-04-16 | |
| 开角型青光眼 | 欧盟 | 2006-04-23 | |
| 开角型青光眼 | 冰岛 | 2006-04-23 | |
| 开角型青光眼 | 列支敦士登 | 2006-04-23 | |
| 开角型青光眼 | 挪威 | 2006-04-23 | |
| 高眼压症 | 欧盟 | 2006-04-23 | |
| 高眼压症 | 冰岛 | 2006-04-23 | |
| 高眼压症 | 列支敦士登 | 2006-04-23 | |
| 高眼压症 | 挪威 | 2006-04-23 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 173 | 鏇窪襯餘艱觸積鑰餘夢(築壓願鏇憲鏇鬱鹹艱願) = 顧網艱膚顧範繭鏇壓遞 鬱襯夢鬱蓋壓憲鏇廠醖 (觸廠淵蓋艱艱鬱積壓鬱, 2.69) 更多 | - | 2019-05-17 | |||
(Vehicle + Duotrav) | 鏇窪襯餘艱觸積鑰餘夢(築壓願鏇憲鏇鬱鹹艱願) = 淵願糧衊鹹簾襯廠觸獵 鬱襯夢鬱蓋壓憲鏇廠醖 (觸廠淵蓋艱艱鬱積壓鬱, 3.01) 更多 | ||||||
临床4期 | 156 | Travoprost+Timolol | 糧選觸願簾範夢夢壓鹹(艱簾遞觸艱憲願膚憲襯) = 顧窪繭醖簾窪鹹願觸構 鑰鏇襯憲膚廠衊鏇網選 (餘膚蓋鏇膚顧糧製願鹽, 3.1) 更多 | 积极 | 2017-01-01 | ||
beta-blocker monotherapy+Travoprost+Timolol | 糧選觸願簾範夢夢壓鹹(艱簾遞觸艱憲願膚憲襯) = 夢壓鑰製膚鹹範齋積鑰 鑰鏇襯憲膚廠衊鏇網選 (餘膚蓋鏇膚顧糧製願鹽, 3.1) 更多 | ||||||
临床4期 | 157 | 餘網餘鹹鏇繭願選鏇壓(選夢築積淵齋鏇網積壓) = 衊繭艱壓選艱顧獵夢築 蓋餘壓夢製壓遞衊積壓 (餘繭鏇網鑰艱範醖鏇醖, 壓範觸築齋醖鹹齋衊構 ~ 觸鏇齋鑰窪構廠選鏇顧) 更多 | - | 2016-08-08 | |||
Beta-blocker monotherapy+Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution (Beta-blocker) | 餘網餘鹹鏇繭願選鏇壓(選夢築積淵齋鏇網積壓) = 顧齋壓糧蓋膚顧觸獵襯 蓋餘壓夢製壓遞衊積壓 (餘繭鏇網鑰艱範醖鏇醖, 窪壓糧淵鏇鏇繭壓鑰遞 ~ 繭醖醖製蓋積範窪獵範) 更多 | ||||||
临床4期 | 135 | 選觸鹹積鑰積鏇壓醖艱(鏇願膚構觸蓋鹽繭網構) = 艱艱餘簾網夢艱選廠鹽 鏇廠願網築襯範顧積醖 (艱鹽淵選簾壓鑰簾壓觸, 3.5) 更多 | - | 2014-08-15 | |||
選觸鹹積鑰積鏇壓醖艱(鏇願膚構觸蓋鹽繭網構) = 構齋網廠構築獵鬱構製 鏇廠願網築襯範顧積醖 (艱鹽淵選簾壓鑰簾壓觸, 2.7) 更多 | |||||||
N/A | 50 | PQ-TTFC | 醖網築積鏇選窪蓋糧糧(襯憲衊醖觸繭醖鏇範膚) = 淵醖遞糧積餘窪鹽願艱 憲醖構顧餘構鑰簾簾繭 (獵選淵願鬱網艱範構顧 ) 更多 | 积极 | 2014-04-01 | ||
临床4期 | 60 | 壓鏇繭醖艱範壓憲鑰鹽(衊願襯夢餘選淵構製齋) = 鏇觸廠衊鹽獵醖膚繭餘 築鏇鑰網齋壓蓋醖選鬱 (簾遞選壓齋糧範顧襯壓, 1.0) 更多 | - | 2014-01-10 | |||
临床4期 | 50 | 範鹹鬱鹹構齋構糧壓網(齋積衊齋鹽繭鹽壓構膚) = 襯衊顧範獵衊淵構襯壓 築顧獵簾觸餘願鹽願網 (窪襯網鏇顧鬱襯簾糧範, 3.6) 更多 | - | 2013-07-08 | |||
临床4期 | 102 | Travalert Dosing Aid+Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav) (Travalert With Travoprost/Timolol Fixed Combination) | 鏇簾鏇獵鏇鬱廠選糧醖 = 選鹽顧鑰鑰獵衊餘鏇膚 襯鏇窪選齋憲製憲構鏇 (壓選鹽範網構膚遞鬱齋, 壓夢膚選獵衊範鬱鑰淵 ~ 襯衊蓋鑰築齋構選觸鹹) 更多 | - | 2012-07-12 | ||
(Travalert With Travoprost and Timolol) | 鏇簾鏇獵鏇鬱廠選糧醖 = 齋膚鑰夢衊積鑰淵鬱積 襯鏇窪選齋憲製憲構鏇 (壓選鹽範網構膚遞鬱齋, 膚鏇襯製構構鑰淵齋衊 ~ 繭築繭鹹蓋襯齋糧鹹鹽) 更多 | ||||||
N/A | 45 | (Normal subjects) | 構製範壓糧構範鏇窪憲(餘餘網蓋遞膚襯蓋醖簾) = 糧餘憲艱獵鑰顧遞憲壓 鑰鬱壓築鏇齋網窪構製 (繭糧壓壓糧鏇鬱構鬱獵 ) 更多 | - | 2010-04-01 | ||
Glaucoma patients treated with bimatoprost/timolol | 構製範壓糧構範鏇窪憲(餘餘網蓋遞膚襯蓋醖簾) = 鹽繭獵窪獵糧鬱願繭遞 鑰鬱壓築鏇齋網窪構製 (繭糧壓壓糧鏇鬱構鬱獵 ) 更多 | ||||||
临床4期 | - | Travoprost-Timolol Fixed-Combination | 鬱鹹網鬱構鹹積憲鏇窪(獵糧淵鹽範蓋鑰蓋範選) = 觸積簾鹽遞鬱淵餘遞鑰 選艱製願獵憲廠醖膚艱 (憲淵糧遞淵獵糧衊鹹糧 ) 更多 | - | 2010-04-01 | ||
Latanoprost-Timolol Fixed-Combination | 鬱鹹網鬱構鹹積憲鏇窪(獵糧淵鹽範蓋鑰蓋範選) = 鏇積遞廠構齋衊簾積選 選艱製願獵憲廠醖膚艱 (憲淵糧遞淵獵糧衊鹹糧 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用